Details of the Drug

General Information of Drug (ID: DMBER0Q)

Drug Name
Hu5F9-G4
Indication
Disease Entry ICD 11 Status REF
Myelodysplastic syndrome 2A37 Phase 3 [1]
B-cell non-hodgkin lymphoma 2B33.5 Phase 1/2 [2]
Colorectal cancer 2B91.Z Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Acute myeloid leukaemia 2A60 Phase 1 [3]
Cross-matching ID
TTD ID
D09JYL
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen CD47 (CD47) TT28S46 CD47_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)